Cipla: Morgan Stanley maintains Underweight on Cipla with Target Price Rs 1,211, citing Lanreotide injection batch recalls from Pharmathen’s Radopi facility, likely delaying US resupply, risking market share loss, and potential downside to FY27–FY28 earnings.

 11 Mar 2026 09:06 AM

Cipla: Morgan Stanley maintains Underweight on Cipla with Target Price Rs 1,211, citing Lanreotide injection batch recalls from Pharmathen’s Radopi facility, likely delaying US resupply, risking market share loss, and potential downside to FY27–FY28 earnings.

Cipla: Cipla USA Starts Recall of Lanreotide Injection Batches, Leading to Short-Term Supply Issues.

 10 Mar 2026 08:05 AM

Cipla: Cipla USA Starts Recall of Lanreotide Injection Batches, Leading to Short-Term Supply Issues.

Cipla: Forms 60:40 Joint Venture With Kemwell Biopharma To Create And Market Biologic Products, Both Partners To Invest Up To 100 Million Rupees

 02 Mar 2026 08:11 PM

Cipla: Forms 60:40 Joint Venture With Kemwell Biopharma To Create And Market Biologic Products, Both Partners To Invest Up To 100 Million Rupees

Cipla: New Subsidiary Established in Saudi Arabia

 02 Mar 2026 07:39 PM

Cipla: New Subsidiary Established in Saudi Arabia

Cipla: MS on Cipla UW, Target Price Rs 1211

 23 Feb 2026 09:14 AM

Cipla: MS on Cipla UW, Target Price Rs 1211

Cipla: USFDA inspection At Co’s Subsidiary Pharmathen’s Facility Was Classified As Official Action Indicated.

 21 Feb 2026 06:16 PM

Cipla: USFDA inspection At Co’s Subsidiary Pharmathen’s Facility Was Classified As Official Action Indicated.

Eli Lilly Aims To Make India A Key Global Export Hub, Says Executive As Part Of Their Supply Chain Strategy - RTRS ( CIPLA )

 18 Feb 2026 09:04 AM

Eli Lilly Aims To Make India A Key Global Export Hub, Says Executive As Part Of Their Supply Chain Strategy - RTRS ( CIPLA )

CIPLA: USFDA Inspects CIPLA's InvaGen Facility In Hauppauge, USA, Receiving Two Observations In Form 483.

 10 Feb 2026 08:57 AM

CIPLA: USFDA Inspects CIPLA's InvaGen Facility In Hauppauge, USA, Receiving Two Observations In Form 483.

CIPLA: Co Reports No Negative Findings From GST Department Inspection in Maharashtra.

 09 Feb 2026 06:45 AM

CIPLA: Co Reports No Negative Findings From GST Department Inspection in Maharashtra.

Cipla: Company Reports Tax Department Begins Inspection At Its Facilities, No Financial Impact Expected

 05 Feb 2026 06:50 PM

Cipla: Company Reports Tax Department Begins Inspection At Its Facilities, No Financial Impact Expected

Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

 27 Jan 2026 09:10 AM

Cipla: Jefferies on Cipla Downgrade to U-P, TP cut to Rs 1170

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285

 27 Jan 2026 09:11 AM

Cipla: HSBC on Cipla Downgrade to Hold, TP cut to Rs 1285

CIPLA: Co In Discussions With Several Partners For CAR-T Cell Therapy Products.

 23 Jan 2026 03:20 PM

CIPLA: Co In Discussions With Several Partners For CAR-T Cell Therapy Products.

Cipla: Co May Venture Into Semaglutide Generics Soon, Partnered With Eli Lilly For Mounjaro Under Yurpeak Brand.

 23 Jan 2026 03:26 PM

Cipla: Co May Venture Into Semaglutide Generics Soon, Partnered With Eli Lilly For Mounjaro Under Yurpeak Brand.

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev.

 23 Jan 2026 01:45 PM

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev.

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev. Decline

 23 Jan 2026 01:45 PM

Cipla: Co CEO Says Upcoming Launches To Cushion Grevlimid Rev. Decline

CIPLA: QUARTERLY BUSINESS WISE SALES PERFORMANCE - NORTH AMERICA SEES A DEGROWTH OF 22% (YOY)

 23 Jan 2026 01:43 PM

CIPLA: QUARTERLY BUSINESS WISE SALES PERFORMANCE - NORTH AMERICA SEES A DEGROWTH OF 22% (YOY)

CIPLA: Q3 EBITDA 12.55B RUPEES VS 19.8B (YOY); EST 15.9B || Q3 EBITDA MARGIN 17.74% VS 28.11% (YOY); EST 22%

 23 Jan 2026 01:29 PM

CIPLA: Q3 EBITDA 12.55B RUPEES VS 19.8B (YOY); EST 15.9B || Q3 EBITDA MARGIN 17.74% VS 28.11% (YOY); EST 22%

CIPLA: CO HAS AN EXCEPTIONAL ITEM OF 2.8B || Q3 PBT 11.7B VS 19B (YOY)

 23 Jan 2026 01:30 PM

CIPLA: CO HAS AN EXCEPTIONAL ITEM OF 2.8B || Q3 PBT 11.7B VS 19B (YOY)

CIPLA: Q3 REVENUE 70.7B RUPEES VS 70.7B (YOY); EST 72.85B

 23 Jan 2026 01:30 PM

CIPLA: Q3 REVENUE 70.7B RUPEES VS 70.7B (YOY); EST 72.85B